

## Intrasense and eCclipseCRO ink a distribution agreement for clinical trials in the United States

**Paris (France) and Exeter, NH (USA), June 25, 2013:** Intrasense, a specialist in multimodal medical imaging software, has announced today they have partnered with eCclipseCRO, a full-service global Contract Research Organization providing clinical services to pharmaceutical, biotechnology and medical device companies worldwide, to resell the Myrian<sup>®</sup> 3D multimodality imaging software suite in the United States for use in clinical trials.

eCclipseCRO President Leslie Bihari, Jr. said, *"eCclipseCRO is very excited to add the cutting-edge Myrian<sup>®</sup> imaging product line to our technology service offering. Teaming with Intrasense completes our clinical technology suite – adding advanced visualization imaging as an assessment tool for the largest, most complicated clinical trials, like in Oncology."*

Intrasense CEO Patrick Mayette stated, *"We are proud to have eCclipseCRO join our international network of partners. Their expertise in implementing advanced clinical data management solutions and providing global services for clinical trials will be a great asset to the deployment of our Myrian<sup>®</sup> solution in the USA. Our American operation will closely support eCclipseCRO."*

### About eCclipseCRO :

eCclipseCRO is a full-service global contract research organization providing clinical data management, biostatistics and clinical operations to pharmaceutical, biotechnology and device companies worldwide. With expertise in oncology, ophthalmology and infectious disease, eCclipseCRO uses leading technology to drive efficiencies that reduce the overall timeline and budget. Eclipscro leverages sophisticated forecasting tools and strong industry experience to optimize drug inventories through worldwide depots, and uses leading software solutions to provide visibility throughout the entire supply chain.

For more about eCclipseCRO, please go to [www.eCclipseCRO.com](http://www.eCclipseCRO.com)

### About Intrasense:

Intrasense designs, develops and markets Myrian<sup>®</sup>, a unique software suite for the visualization and advanced processing of multimodal medical images (MRI, CT scans, PET, X-rays, etc.). Developed with leading academic partners, Myrian<sup>®</sup> combines and uses all of the various medical images to extract information that is vital to the patient's care, to the rapid appraisal of the efficiency of treatment and, therefore, to assessing drug candidates in oncology and other pathologies. With over 700 client sites around the world, Myrian<sup>®</sup> has been certified as a "medical device" in over 40 countries, in the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on NYSE Alternext (FR0011179886 – ALINS).

For more about Intrasense, please go to [www.intrasense.fr](http://www.intrasense.fr)

### CONTACTS

eCclipseCRO  
Leslie Bihari  
President

Intrasense  
Patrick Mayette  
Directeur Général  
Tél. : 01 44 78 92 53  
[investisseurs@intrasense.fr](mailto:investisseurs@intrasense.fr)

NewCap.  
Communication financière et relations investisseurs  
Valentine Brouchet / Pierre Laurent  
Tél. : 01 44 71 94 96  
[intrasense@newcap.fr](mailto:intrasense@newcap.fr)

**ALINS**  
**LISTED**  
**NYSE**  
**ALTERNEXT**